Mandara Biopharma Files IND with the FDA to Advance Dronabinol Oral Solution Formulation for Alzheimer’s Agitation
Mandara Biopharma Inc., a privately held U.S.-based biopharmaceutical company focused on novel therapies for central nervous system (CNS) disorders, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate clinical development of its dronabinol oral solution formulation for the treatment of agitation associated […]